Pancreatic Neuroendocrine Tumor clinical trials

Explore recruiting pancreatic neuroendocrine tumor clinical trials.

Recruiting pancreatic neuroendocrine tumor studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pancreatic Neuroendocrine Tumor trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

First adjuvant trial in locally resected aggressive pancreatic neuroendocrine tumors: a randomized phase III investigating the efficacy of systemic chemotherapy (ADJUPANET)

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter single-arm pilot study of ramucirumab in combination with dacarbazine in patients with progressive well differentiated metastatic pancreatic neuroendocrine tumors

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients with Neuroendocrine Neoplasms

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase IIa Clinical Trial: Feasibility Study on Non-Invasive Simultaneous Hyperpolarized [1-13C]Pyruvate Magnetic Resonance Spectroscopy and 18F-FDG PET (hyperPET) for Metabolic Imaging in Patients with Cancer

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients (SAUNA trial)

Netherlands, Belgium

Therapeutic use (Phase IV) EU CTIS Study details

A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long‑term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)

Czechia, Spain, Poland, Belgium, Finland, Germany +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Pancreatic Neuroendocrine Tumor trials by city

Pancreatic Neuroendocrine Tumor in Toronto Pancreatic Neuroendocrine Tumor in Vancouver Pancreatic Neuroendocrine Tumor in Montreal Pancreatic Neuroendocrine Tumor in Calgary Pancreatic Neuroendocrine Tumor in Edmonton Pancreatic Neuroendocrine Tumor in Ottawa Pancreatic Neuroendocrine Tumor in Winnipeg Pancreatic Neuroendocrine Tumor in Quebec City Pancreatic Neuroendocrine Tumor in Hamilton Pancreatic Neuroendocrine Tumor in Kitchener Pancreatic Neuroendocrine Tumor in London Pancreatic Neuroendocrine Tumor in Halifax Pancreatic Neuroendocrine Tumor in New York Pancreatic Neuroendocrine Tumor in Los Angeles Pancreatic Neuroendocrine Tumor in Chicago Pancreatic Neuroendocrine Tumor in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease